

BIBLIOGRAPHY

- Aarestrup, J., Trabert, B., Ulrich, G., Wentzensen, N., Sørensen, A., & Baker, L. 2019. 'Childhood overweight, tallness, and growth increase risks of ovarian cancer', *Cancer Epidemiology, Biomarkers & Prevention*, 28(1), pp. 183–188. doi: 10.1158/1055-9965.epi-18-0024.
- Adhikari, L. and Hassell, L. 2021. *Who classification, Pathology Outlines - WHO classification*. Available at: <https://www.pathologyoutlines.com/topic/ovarytumorwhoclassif.html>
- American Cancer Society. 2018. *What causes ovarian cancer: How do you get ovarian cancer, What Causes Ovarian Cancer | How Do You Get Ovarian Cancer*. Available at: <https://www.cancer.org/cancer/types/ovarian-cancer/causes-risks-prevention/what-causes.html>
- American Cancer Society. 2022. *Invasive epithelial ovarian cancer treatment, by stage, Invasive Epithelial Ovarian Cancer Treatment, by Stage*. Available at: <https://www.cancer.org/cancer/types/ovarian-cancer/treating/by-stage.html#:~:text=The%20initial%20treatment%20for%20stage,sub%2Dstage%20of%20the%20cancer> (Accessed: 16 June 2023).
- American Cancer Society. 2023. *Ovarian cancer statistics: How common is ovarian cancer*. Available at: <https://www.cancer.org/cancer/types/ovarian-cancer/about/key-statistics.html#:~:text=Ovarian%20cancer%20ranks%20fifth%20in,is%20about%201%20in%20108>
- Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Chen, L., Cristea, M., DeRosa, M., Eisenhauer, E. L., Gershenson, D. M., Gray, H. J., Grisham, R., Hakam, A., Jain, A., Karam, A., Konecny, G. E., Leath, C. A., III, Liu, J., Mahdi, H., Martin, L., Matei, D., McHale, M., McLean, K., Miller, D. S., O'Malley, D. M., Percac-Lima, S., Ratner, E., Remmenga, S. W., Vargas, R., Werner, T. L., Zsiros, E., Burns, J. L., and Eng, A. M. (2021). Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network* 19, 2, 191-226, DOI: 10.6004/jnccn.2021.0007
- Arora T, Mullangi S, Lekkala MR. *Ovarian Cancer*. 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK567760/>
- Barnes, B.M., Nelson, L., Tighe, A. Burghel, G., Lin, I., Desai, S., McGrail, J., Morgan, R., & Taylor, S. 2021. Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes. *Genome Med* 13, 140. <https://doi.org/10.1186/s13073-021-00952-5>
- Boyraz, G., Başaran, D., Salman, M.C. 2017. Stage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy. *Journal of the Turkish-German Gynecological Association*, 18(1), 33-37. doi:10.4274/jtgga.2016.0190.
- Cancer Genome Atlas Research Network. 2012. Integrated genomic analyses of ovarian carcinoma. *Nature*.474(7353):609-15. doi: 10.1038/nature10166.



UNIVERSITAS
GADJAH MADA

The Effect of Histological Subtypes of Ovarian Carcinoma on Overall Survival of Patients Who Underwent Primary Surgery at RSUP Dr. Sardjito
TIARA FADHILAH, Dr. dr. Moh. Nailul Fahmi, Sp. OG, Subsp. Onk.; Dr. Drs. Abdul Wahab, MPH
Universitas Gadjah Mada, 2024 | Diunduh dari <http://etd.repository.ugm.ac.id/>

- Chang, L.C., Huang, C.F., Lai, M.S., Shen, L.J., Wu, F.L. L., & Cheng, W.F. 2018. Prognostic factors in epithelial ovarian cancer: A population-based study. *PLOS ONE*, 13(3). <https://doi.org/10.1371/journal.pone.0194993>
- FIGO. 2018. *Staging for OVFTP malignancies, Figo*. Available at: <https://www.figo.org/news/staging-ovftp-malignancies> (Accessed: 16 June 2023).
- Green, A. 2022. *Ovarian cancer, Practice Essentials, Background, Pathophysiology*. Available at: <https://emedicine.medscape.com/article/255771-overview#a1>
- Henderson, J.T., Webber, E.M. and Sawaya, G.F. 2018. 'Screening for ovarian cancer', *JAMA*, 319(6), p. 595. doi:10.1001/jama.2017.21421.
- Hendrikson, J., Liu, Y., Tan, Q., Tan, Joey., Ng, G., Chong, C., Seo, C., Wong, J., Chia, C., Ong, C. 2023 'Abstract 989: Ascites in colorectal peritoneal carcinomatosis supersedes mutational status and other clinical variables as negative prognostic factor for CRS-HIPEC via EMT pathway', *Cancer Research*, 83(7_Supplement), pp. 989–989. doi:10.1158/1538-7445.am2023-989.
- Hippisley-Cox J, Coupland C. 2011. Identifying women with suspected ovarian cancer in primary care: derivation and validation of algorithm. *BMJ*. 4;344:d8009. doi: 10.1136/bmj.d8009. PMID: 22217630; PMCID: PMC3251328.
- Hosono, S., Kajiyama, H., Mizuno, K., Sakakibara, K., Matsuzawa, K., Takeda, A., Kikkawa, F. 2011. 'Comparison between serous and non-serous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgery', *International Journal of Clinical Oncology*, 16(5), pp. 524–532. doi:10.1007/s10147-011-0223-5.
- Hsieh, S.-F. *et al.* 2019. 'Prognostic factors of early stage epithelial ovarian carcinoma', *International Journal of Environmental Research and Public Health*, 16(4), p. 637. doi:10.3390/ijerph16040637.
- Koshiyama, Masafumi, Noriomi Matsumura, and Ikuo Konishi. 2017. "Subtypes of Ovarian Cancer and Ovarian Cancer Screening" *Diagnostics* 7, no. 1: 12. <https://doi.org/10.3390/diagnostics7010012>
- Králíčková, M., Laganà, A.S., Ghezzi, F., Vetvicka, V. 2020. Endometriosis and risk of ovarian cancer: what do we know? *Arch Gynecol Obstet* **301**, 1–10. <https://doi.org/10.1007/s00404-019-05358-8>
- Lheureux S, Gourley C, Vergote I, Oza AM. 2019. Epithelial ovarian cancer. *Lancet*. doi: 10.1016/S0140-6736(18)32552-2. PMID: 30910306.
- Li, J., Li, X., Ma, J., Wang, F., Cui, S. 2022. Computed tomography–based radiomics machine learning classifiers to differentiate type I and type II epithelial ovarian cancers. *Eur Radiol*. <https://doi.org/10.1007/s00330-022-09318-w>



- Luk, H. M., Wang, D. Y., Xie, L. L., Liu, X. Y., Xu, G. C., & Lu, H. W. 2020. Expression and clinical significance of Gal-3 and NF κ B pathway-related factors in epithelial ovarian carcinoma. *International journal of clinical and experimental pathology*, 13(5), 1197–1205.
- Maleki, Z., Vali, M., Nikbakht, HA. *et al.* Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis. *BMC Cancer* **23**, 558 (2023).
<https://doi.org/10.1186/s12885-023-11041-8>
- Manchana, T. and Kobwitaya, K. (2018) ‘Survival Outcomes for Different Subtypes of Epithelial Ovarian Cancer’, *Clinical Research in Obstetrics and Gynecology*, 1(1).
- Markman, M. 2022. *Types of ovarian cancer: Common, rare and more, Ovarian Cancer Types*. Available at: <https://www.cancercenter.com/cancer-types/ovarian-cancer/types>
- Momenimovahed, Z. Tiznobaik, A., Taheri, S., Salehiniya, H. 2019. Ovarian cancer in the world: Epidemiology and risk factors, *International Journal of Women’s Health*, Volume 11, pp. 287–299. doi:10.2147/ijwh.s197604.
- Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjær S, Lidegaard Ø. 2009. Hormone Therapy and Ovarian Cancer. *JAMA* ;302(3):298–305. doi:10.1001/jama.2009.1052
- Nasser, S., Fotopoulou, C., Richter, R., Kaulich, J., Braicu, E., Beteta, C., Olschewski, J., Babayeva, A., & Sehouli, J. (2021). Prognostic Value and Therapeutic Implications of Pleural Carcinosis and Malignant Pleural Effusion in Advanced Epithelial Ovarian Cancer. *Anticancer research*, 41(4), 2033–2038. <https://doi.org/10.21873/anticancer.14971>
- National Cancer Institute. 2020. *Cancer of the ovary - cancer stat facts, Cancer Stat Facts: Ovarian Cancer*. Available at: <https://seer.cancer.gov/statfacts/html/ovary.html>
- National Cancer Institute. 2023. *Ovarian, fallopian tube, & primary peritoneal cancers prevention (PDQ®), National Cancer Institute*. Available at: https://www.cancer.gov/types/ovarian/hp/ovarian-prevention-pdq#link/_15
- NHS UK. 2023. *Comorbidities and cancer, NHS choices*. Available at: <https://digital.nhs.uk/ndrs/our-work/ncras-work-programme/comorbidities-and-cancer#:~:text=What%20is%20a%20comorbidity%3F,treatment%20or%20receiving%20standard%20treatment.>
- Webb, P., Jordan, S. 2017 Epidemiology of epithelial ovarian cancer, *Best Practice & Research Clinical Obstetrics & Gynaecology*, Volume 41, Pages 3-14, ISSN 1521-6934, <https://doi.org/10.1016/j.bpobgyn.2016.08.006>
- Rojas V, Hirshfield KM, Ganesan S, Rodriguez-Rodriguez L. Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. *International Journal of Molecular Sciences*. 2016; 17(12):2113. <https://doi.org/10.3390/ijms17122113>
- Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS. 2010. "Predictive Value of Symptoms for Early Detection of Ovarian Cancer". *J Natl Cancer Inst*. 102 (4): 222–9.



UNIVERSITAS
GADJAH MADA

The Effect of Histological Subtypes of Ovarian Carcinoma on Overall Survival of Patients Who Underwent Primary Surgery at RSUP Dr. Sardjito

TIARA FADHILAH, Dr. dr. Moh. Nailul Fahmi, Sp. OG, Subsp. Onk.; Dr. Drs. Abdul Wahab, MPH

Universitas Gadjah Mada, 2024 | Diunduh dari <http://etd.repository.ugm.ac.id/>

- Sait KH, Alam MZ, Haque A, Sait HK, Sait MK, Anfinan NM. Survival and prognostic factors in women treated for epithelial ovarian cancer in western region of Saudi Arabia. *Saudi Med J*. 2022 Feb;43(2):146-155. doi: 10.15537/smj.2022.43.2.20210626. PMID: 35110339; PMCID: PMC9127918.
- Slavchev S, Kornovski Y, Yordanov A, Ivanova Y, Kostov S, Slavcheva S. Survival in Advanced Epithelial Ovarian Cancer Associated with Cardiovascular Comorbidities and Type 2 Diabetes Mellitus. *Current Oncology*. 2021; 28(5):3668-3682. <https://doi.org/10.3390/curroncol28050313>
- Suchetha S, Thanooja S, Rema P, Ammu JV. 2023. Clinical Profile and Survival Outcome of Type 1 and Type 2 Ovarian Cancers - A Comparative Study in A Tertiary Cancer Care Hospital in Kerala, *International Journal of Academic Medicine and Pharmacy*, 5(2). doi:10.47009/jamp.2023.5.2.239.
- Tamirisa, N., Lin, H., Shen, Y., Shaitelman, S. F., Sri Karuturi, M., Giordano, S. H., Babiera, G., & Bedrosian, I. (2020). Association of Chemotherapy with Survival in Elderly Patients with Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer. *JAMA oncology*, 6(10), 1548–1554. <https://doi.org/10.1001/jamaoncol.2020.2388>
- Zhou J, Wu SG, Wang J, Sun JY, He ZY, Jin X, Zhang WW. 2018. The Effect of Histological Subtypes on Outcomes of Stage IV Epithelial Ovarian Cancer. *Front Oncol*. doi: 10.3389/fonc.2018.00577.